Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Kaufen / Verkaufen

Top-Partner CFD-Broker

Plus500
  • Keine Kommissionen, enge Spreads
  • Hebel- und Long/Short-Trading, fortgeschrittene Analysetools, kostenlose Echtzeitkurse etc.
  • CFD-Trading auf Aktien, Indizes, Krypto, Rohstoffe und Devisen
Direkt zu Plus500 CFD service. Ihr Kapital unterliegt einem Risiko.

Premium-Partner

IG Bank
  • Ein weltweit führender CFD-Anbieter*, FINMA-reguliert
  • Über 17'000 Märkte: Indizes, Devisen, Rohstoffe, Aktien, Kryptowährungen, Optionen und mehr
  • Erweiterte Handelszeiten und Wochenendhandel
  • Schweizer Kundenserviceteam, mit Büros in Genf und Zürich
*Die IG Gruppe ist grösster Anbieter nach Umsatz (veröffentlichter Geschäftsbericht 2022)
Direkt zur IG Bank Verluste können Einlagen übersteigen.
Saxo Bank
  • Lizenzierte Schweizer Bank (FINMA)
  • Keine Depotgebühren bei aktivierter Wertpapierleihe
  • Aktien, ETFs, Optionen, FX, CFDs, Futures, Rohstoffe, Bonds, Mutual Funds - auf einer Plattform
  • Gratis Expertenanalysen und Trading-Signale
  • Saxo Deal: Rückerstattung der Courtagen bis CHF 200 während 90 Tagen
Direkt zur Saxo Bank
Werbung
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
05.12.2024 12:10:03

EQS-News: Viromed Medical AG: Cooperation between relyon plasma GmbH and Viromed Medical GmbH

Fonterelli SPAC 2
2.46 EUR -2.38%
Kaufen / Verkaufen

EQS-News: Viromed Medical AG / Key word(s): Alliance
Viromed Medical AG: Cooperation between relyon plasma GmbH and Viromed Medical GmbH

05.12.2024 / 12:10 CET/CEST
The issuer is solely responsible for the content of this announcement.


Viromed Medical AG: Cooperation between relyon plasma GmbH and Viromed Medical GmbH

Pinneberg/Regensburg, 5 December 2024 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) is pleased to inform about the cooperation between its subsidiary Viromed Medical GmbH and relyon plasma GmbH, a subsidiary of TDK Electronics AG (link to the original news: https://www.relyon-plasma.com/cooperation-relyon-plasma-gmbh-and-viromed/).

relyon plasma GmbH, a subsidiary of TDK Electronics AG, and Viromed Medical GmbH are jointly researching the use of cold atmospheric pressure plasma in medicine. Here, relyon plasma is responsible for developing the technology that utilizes plasma. Within the cooperation, Viromed is responsible for the approval of the device and its distribution.

Viromed Medical GmbH has been involved in basic research into viruses and bacteria since 2004 and is revolutionizing medical technology using cold atmospheric plasma in room air purification, wound healing and intensive care medicine.

Plasma in dermatology
Viromed has developed the ViroCAP® system based on relyon plasma's piezoelectric direct discharge technology. This device is designed to use cold atmospheric pressure plasma in dermatology. Uwe Perbandt, CEO of Viromed Medical AG, describes the treatment approach as follows: “Treatment with the ViroCAP® activates the body's own regeneration processes. This process occurs with the help of reactive species that stimulate cell metabolism. In this way, the entire wound healing process is activated.”

At Arab Health, the global healthcare exhibition in Dubai, from 27th – 30th January 2025, relyon plasma will be presenting the ViroCAP® system from Viromed for the first time in addition to its existing products PiezoBrush PZ3 and MediPlas system.

MediPlas RONS generator in infection research
In addition, the two companies, together with the Hannover Medical School and the expert network BREATH (Biomedical Research in End-stage and Obstructive Lung Disease Hannover) from the German Centre for Lung Research (DZL) and the Helmholtz Institute for Infection Research (HZI), are investigating the disinfecting effect of plasma using the MediPlas RONS (Reactive oxide and nitrogen species) generator in infection research. The aim of the co-operation is to investigate the safety and effectiveness of cold plasma for eliminating bacteria in the respiratory tract to prevent ventilator-associated pneumonia (VAP). The aim is to develop a novel, non-antibiotic preventive measure to protect patients from this serious complication.

As a partner of Viromed, relyon plasma will establish the prototypes for the application and ensure the standardized generation of cold plasma as well as its characterization and consistency in the execution of the tests. Viromed Medical AG holds the exploitation rights.

Simona Lerach, Managing Director of relyon plasma GmbH, summarizes the cooperation: “We are delighted to have partnered with Viromed, an innovative company in the medical field that is conducting in-depth research and development into the use of cold atmospheric pressure plasma in medicine with our components.”

 

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.

About relyon plasma GmbH

Relyon plasma GmbH, based in Regensburg, Germany, is a subsidiary of TDK Electronics AG. True to its motto "rely on plasma", the company sees itself as a professional supplier of innovative plasma systems and a service provider for customer-specific process solutions. Thanks to many years of professional experience in the industry, relyon plasma offers a wide range of specialized plasma components for manual applications and inline processes. Atmospheric pressure plasma is used to disinfect, clean, modify and functionalize a wide variety of surfaces. The materials can thus be optimally prepared for bonding, painting and printing.

 

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de

 

Contact reylon plasma GmbH

relyon plasma GmbH
Osterhofener Str. 6
93055 Regensburg
Andrea Eichinger
+49 941 60098270
andrea.eichinger@tdk.com
www.relyon-plasma.com



05.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg
EQS News ID: 2044321

 
End of News EQS News Service

2044321  05.12.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2044321&application_name=news&site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6

Analysen zu Fonterelli SPAC 2 AG Inhaber-Akt

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Die Assetklasse Private Debt erklärt | BX Swiss TV

Private Debt: Die rasant wachsende Anlageklasse mit grossem Potenzial für Investoren und Unternehmen!

Im Experteninterview mit Kirsten Bode von Muzinich & Co und Olivia Hähnel von der BX Swiss erfahren Sie, warum Private Debt eine spannende Alternative zur traditionellen Kreditfinanzierung ist. Die Anlageklasse ermöglicht Investoren eine sinnvolle Diversifikation, bietet attraktive Illiquiditätsprämien und zeichnet sich durch eine geringe Volatilität aus. Gleichzeitig profitieren mittelständische Unternehmen von flexiblen Finanzierungslösungen, um Wachstum und Projekte voranzutreiben. Insbesondere in Europa hat sich der Markt in den letzten zehn Jahren verdreifacht und bietet über neue Fondsmodelle auch Privatanlegern Zugang. 2025 könnte ein entscheidendes Jahr für Private Debt werden – dank sinkender Zinsen und steigender Nachfrage. Ein absolutes Muss für alle, die ihre Anlagestrategie um zukunftsträchtige Optionen erweitern wollen!

 

👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!

Die Assetklasse Private Debt erklärt | BX Swiss TV

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’200.00 19.91
Short 12’449.68 13.97 OGSSMU
Short 12’938.57 8.82 CIUBSU
SMI-Kurs: 11’740.52 17.12.2024 17:30:19
Long 11’232.83 19.24 S5TMZU
Long 11’001.47 13.89 SSRMMU
Long 10’528.51 8.96 5SSMZU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten